Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries[@b1]. In the United States, a total of 1,660,290 new cancer cases and 580,350 cancer deaths were projected to occur in 2013[@b2]. In Europe, there were an estimated 3.45 million new cases of cancer (excluding non-melanoma skin cancer) and 1.75 million deaths from cancer in 2012[@b3]. Furthermore, the global burden of cancer continues to increase, largely because of population growth and increased life-expectancy[@b3]. Invasion and metastasis are two important hallmarks of cancer and are responsible for the majority of cancer deaths[@b4]. Although much effort has been devoted to the diagnosis and therapy of cancers, the overall prognosis is still unsatisfactory. A lack of knowledge of molecular biomarkers in cancer has limited the development of personalized therapies and improvements in survival. Therefore, there is an urgent need for universal, effective, readily available and inexpensive biomarkers in solid tumors to identify patients with a poor prognosis so that novel treatments can be initiated earlier.

The metabolism of cancer cells differs from that of normal cells. This is largely because cancer cells exhibit metabolic alterations that are frequently associated with reprogramming. Unlike normal cells, cancer cells preferentially metabolize glucose by glycolysis to generate sufficient energy for the demands of rapid proliferation, even in the presence of adequate oxygen[@b5].This phenomenon is known as the Warburg effect and is one of the predominant metabolicalterations that occur during malignant transformation. In this process, transcriptional programs regulated by oncogenes stabilize hypoxia-inducible factor 1 alpha (HIF-1α). HIF-1α contributes to the upregulation of most enzymes involved in the glycolytic pathway, including lactate dehydrogenase (LDH).In the final step of aerobic glycolysis, LDH converts pyruvate tolactate, which is coupled with the oxidation of NADH to NAD+. These metabolic changes are reflected by an elevated serum LDH level[@b6](hereinafter LDH).

Elevated LDH has been recognized as a poor prognostic indicator in cancer for many years[@b7][@b8][@b9][@b10]. LDH has also been incorporated in prognostic scores for several types of cancer[@b11]. However, the consistency and magnitude of the prognostic impact of LDH are unclear[@b12][@b13][@b14]. The aim of this study was to review published studies and use standard meta-analytic techniques to quantify the prognostic value of LDH in various solid tumors.

Methods
=======

Data sources and searches
-------------------------

This analysis was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines[@b15]. PubMed was searched for studies evaluating the LDH and survival in solid tumors from 1978 to 2014. We used various medical subject heading terms, including "l-lactate dehydrogenase", "prognosis", "multivariate analysis" and "proportional hazard model". Title/abstract words included "lactate dehydrogenase", "LDH", "prognosis", "prognose", "prognostic", "multivariate analysis", "proportional hazard model", "COX proportional hazard model" and "COX models". The full search strategy is described in the [Supplementary Methods](#s1){ref-type="supplementary-material"} (available online).

Study selection
---------------

Inclusion criteria for the primary analysis were as follows: 1) studies of people with solid tumors reporting on the prognostic impact of LDH; 2) prospective or retrospective cohort design with a clearly defined source population and justifications for all excluded eligible cases; 3) sample size greater than 200; 4)statistical analysis using multivariate proportional hazards modeling that adjusted for clinical prognostic factors; and 5) reporting of the resultant adjusted hazard ratios (HRs) and their 95% confidence intervals (CIs) or a P value for overall survival (OS). For the secondary analyses, studies providing a HR for cancer-specific survival (CSS), progression-free survival (PFS), disease-free survival (DFS), or recurrence-free survival (RFS) were included as well.

Data extraction
---------------

OS was the primary outcome of interest. CSS, PFS, and DFS were secondary outcomes. Two authors (J.Z. and H.W.) independently extracted information using predefined data abstraction forms. The following details were extracted: name of first author, year of publication, number of patients included in analysis, disease site, disease stage (non-metastatic, metastatic, mixed \[both non-metastatic and metastatic\]), study type (prospective or retrospective), cutoff defining high LDH, and HRs and associated 95% confidence intervals for OS, PFS, DFS, or RFS as applicable. HRs were extracted preferentially from multivariate analyses where available. Where several HR values were given in an article, the value adjusted for most confounders was used.

Data synthesis
--------------

The meta-analysis was conducted initially for all included studies for each of the endpoints of interest. Subgroup analyses were conducted for predefined parameters such as disease site, disease stage and LDH cutoff, and all data were limited to multivariate analyses. Disease site subgroups were generated if at least three studies on that site were available; the remaining studies were pooled in a subgroup termed "other." LDH cutoff subgroups were \< 250 U/L, 250--300 U/L, 301--400 U/L, and \>400 U/L. In three studies, the effect of LDH was reported as a continuous variable; we pooled those studies separately. Univariate meta-regression model analysis was performed to evaluate the relationship between covariates (LDH cutoff) and the HR for OS.

Statistical analyses
--------------------

The meta-analysis was performed with RevMan 5.2 analysis software (Cochrane Collaboration, Copenhagen, Denmark). Estimates of HRs were weighted and pooled using the generic inverse-variance and random-effect model[@b16]. Analyses were conducted for all studies, and differences between the subgroups were assessed using methods described by Deeks et al.[@b17]. Publication bias was assessed by visual inspection of the funnel plot. Heterogeneity was assessed using Cochran Q and I^2^ statistics. Meta-regression analysis was conducted using Stata12.0 software. All statistical tests were two-sided, and statistical significance was defined as P less than 0.05. No correction was made for multiple testing.

Results
=======

Description of studies
----------------------

Sixty-eight studies were included in the meta-analysis. The selection process for the systematic review is shown in Figure S1 and the characteristics of the included studies are shown in [Table 1](#t1){ref-type="table"}. A total of 31,857 patients were included and the median trial sample size was 363.

Overall survival
----------------

Sixty-three studies comprising 29,620 patients reported HRs for OS. All studies analyzed LDH as a dichotomous variable. The studies have clearly shown that upper limit of normal (ULN) remains common for high LDH. The median cutoff for high LDH was 250U/L (range = 200--1000).

Two of the 63 eligible studies (3.2%) reported a non-statistically significant HR. A forest plot of all studies is presented in [Figure 1](#f1){ref-type="fig"}. Overall, LDH greater than the cutoff was associated with a HR for OS of 1.48 (95% CI = 1.43 to 1.53; P \< 0.00001). As the heterogeneity among studies was significant (P \< 0.00001; I^2^ = 93%), a random-effects model was applied. To explore potential sources of heterogeneity, we performed subgroup analysis in the following subgroups: disease site, tumor stage, and LDH subdivided by predefined cutoffs.

The effect of LDH on OS among disease subgroups is shown in [Figure 2](#f2){ref-type="fig"}. The prognostic effect of LDH was highest in renal cell carcinoma (HR = 1.84, 95% CI = 1.35 to 2.51), followed by nasopharyngeal carcinoma (HR = 1.82, 95% CI = 1.48 to 2.24), sarcoma (HR = 1.79, 95% CI = 1.30 to 2.47), melanoma (HR = 1.76, 95% CI = 1.56 to 1.98), prostate cancer (HR = 1.55, 95% CI = 1.06 to 2.26), colorectal cancer (HR = 1.52, 95% CI = 1.29 to 1.79), and lung cancer (HR = 1.50, 95% CI = 1.27 to 1.78). The HR for the subgroup of other unselected solid tumors was 1.69 (95% CI = 1.44 to 2.00). For the eight disease-site subgroups analyzed, there was statistically significant heterogeneity between disease sites (P \< 0.00001), but no significant differences in the prognostic values of LDH between the subgroups (P for subgroup difference = 0.68).

The effect of LDH on OS among different disease stages is shown in [Figure 3](#f3){ref-type="fig"}. The HRs were 1.54 (95% CI = 1.32 to 1.80) for non-metastatic disease, 1.70 (95% CI = 1.59 to 1.82) for metastatic disease, and 1.20 (95% CI = 1.16 to 1.24) for a mixed group consisting of studies that included both metastatic and non-metastatic patients. There was statistically significant heterogeneity between disease stages (P \< 0.00001). The prognostic value of LDH also varied significantly between different disease stages (P for subgroup difference \< 0.00001).

The effect of LDH on OS among different cutoffs for LDH is shown in [Figure 4](#f4){ref-type="fig"}. The HRs were 1.71 (95% CI = 1.38 to 2.12) for LDH cutoff \< 250U/L, 1.67(95% CI = 1.52 to 1.84) for LDH cutoff 250 to 300U/L, 1.69 (95% CI = 1.27 to 2.24) for LDH cutoff 301 to 400U/L, and 1.72(95% CI = 1.45 to 2.05)for LDH cutoff \> 400 U/L. There was no statistically significant heterogeneity between the different cutoffs for LDH (P for subgroup difference = 0.99).

The scatter plot for the univariate meta-regression analysis is shown in [Figure 5](#f5){ref-type="fig"}.A total of 63 studies was included in the meta-regression analysis. Overall, there was no statistically significant association between LDH cutoff and the HR for OS (P = 0.614).

There was evidence of publication bias, with fewer small studies reporting negative results than would be expected ([Supplementary Figure S2](#s1){ref-type="supplementary-material"}).

Three studies, comprising 1,766 patients, analyzed LDH as a continuous variable and reported HRs for OS. The pooled summary HR of these studies was 2.11 (95% CI, 1.35--3.28; P = 0.0003; I^2^ = 84%) per incremental LDH unit ([Supplementary Figure S5](#s1){ref-type="supplementary-material"}).

Progression-free survival
-------------------------

Six studies, comprising 2,451 patients, reported HRs for PFS. Overall, LDH greater than the cutoff was associated with a HR for PFS of 1.70 (95% CI = 1.44 to 2.01; P \< 0.00001; I[@b2] = 13%). A forest plot is presented as Figure S3.

Disease-free (Recurrence-free) survival
---------------------------------------

A total of five trials, comprising 1,992 patients, reported HRs for DFS. Overall, LDH greater than the cutoff was associated with a HR for the endpoints of 1.86 (95% CI = 1.15 to 3.01; P = 0.01; I[@b2] = 88%). A forest plot is presented in Figure S4.

Discussion
==========

This is the first comprehensive meta-analysis of the prognostic relevance of LDH in solid tumors and it is based on a large pool of clinical studies (31,857 patients). We found a consistent effect of an elevated LDH on OS (HR = 1.48, 95%CI = 1.43 to 1.53) across all disease subgroups and stages. In addition, there is a trend toward a stronger prognostic value of LDH in metastatic disease compared with non-metastatic disease, which may reflect greater tumor burden. The prognostic impact of LDH on PFS and DFS (or RFS) is also robust. Interestingly, different cutoffs of LDH for different disease sites were reported in the included studies. However, the result of subgroups analysis for LDH cutoff showed that there was no association between LDH cutoff and reported HR for OS. This result was confirmed by meta-regression of LDH cutoff and HR for OS. Moreover, LDH was also related to poor prognosis in solid tumors when analyzed as a continuous variable. Our conclusions are supported by the fact that our selected studies were confined to those that used proportional hazards modeling to adjust for clinical prognostic factors and where the sample size was greater than 200.

There is a good biologic rationale for the use of LDH as a prognostic marker for cancer patients; however, the exact mechanism is not understood. One potential mechanism may be an association between LDH and the well-established phenomenon of oncogenicanaerobic glycolysis, or the Warburg effect[@b5]. This metabolic reprogramming is regulated by HIF-1α, as well as myc, through the transcriptional activation of key genes encoding metabolic enzymes; these include LDH, which converts pyruvate to lactate. This process is closely associated with an increased risk of invasion, metastasis, and patient death[@b77].

These analyses have several important implications. First, they show that a high LDH is associated with worse outcome, which suggests that LDH may be a useful biomarker to direct therapeutic selection[@b78][@b79].This is because LDH is under the translational control of HIF-1α, as well as myc, and thus is regulated by key oncogenic processes, such as the phosphatidylinositol 3-kinase/Akt/TORC1/hypoxia-inducible factor (PI3K/Akt/TORC1/HIF) pathway[@b80][@b81][@b82]. A recent study has demonstrated that the TORC1 inhibitor, temsirolimus, could provide therapeutic benefit in patients with RCC and high LDH[@b79]. Further work to investigate the predictive value of pretreatment LDH in other solid tumors may provide a more general insight into which patients derive benefit from TORC1 inhibition. Second, they show that increased LDH may be interpreted as reflecting high tumor burden or tumor aggressiveness. This suggests that dynamic changes of LDH level may be useful for predicting the prognosis in cancer patients after a primary operation, adjuvant chemotherapy, hormonal therapy, or radiotherapy[@b65]. Third, LDH allows the identification of a subgroup of tumors with a worse outcome. It is essential in the treatment of cancer to distinguish between low- and high-risk patients, thereby allowing stratification for standard or intensified treatment protocols. It has been shown that LDH can be used as an effective biomarker to guide the selection of regorafenib in patients with colorectal cancer; patients with high LDH may not be optimal candidates for regorafenib[@b83].To adequately address these issues and dissect the complex relationship between LDH and cancer, future studies should be conducted within tumor- and stage-specific cohorts.

The strengths of this meta-analysis include the large sample size, estimation of HR using multivariate proportional hazards modeling that adjusted for clinical prognostic factors, and analysis of a massive dataset comprising a large pool of clinical studies. LDH is also likely to be a cancer-specific biomarker, given that it is rarely increased in patients without cancer[@b84]. Thus, LDH may be a universal prognostic marker in cancer. To improve research in this area, studies with a more specific focus, such as those that address the impact of an individual LDH level on the prognosis of a homogeneous population of cancer patients (i.e., patients with the same cancer stage and subtype), would likely be more informative.

These analyses have limitations. One of the main limitations is the significant heterogeneity between studies, although we used random-effects models when pooling subgroup data. The heterogeneity in these studies could be explained by different patient characteristics or study designs. To facilitate interpretation, we grouped the patients by tumor type and tumor stage. Another limitation is that this is a literature-based analysis. It is compromised by the potential for publication bias, in which there is a tendency for predominantly positive results to have been published, thus inflating our estimate for the association between LDH and outcome. Our strict inclusion criteria (study size greater than 200, the requirement for HRs, and a requirement for a 95% CI or P value) may have introduced selection bias. Most of the included studies were retrospective, which may have introduced reporting bias. Finally, different cutoffs used to assess high LDH level in these studies might also have contributed to the heterogeneity because it is possible that more false-positive cases were obtained with a cutoff of \< 300 U/L than with a cutoff of \>300 U/L. However, there is no accepted and validated absolute LDH level above which high LDH can be assigned. Instead, we used a cutoff of ULN. This may have introduced substantial heterogeneity, which may not have been fully accounted for by our use of sensitive analyses. The use of ULN is less robust; however, this was the only feasible method with the data available. An internationally accepted and validated LDH cutoff is warranted.

In summary, our data suggest that pretreatment LDH is a simple, cost-effective prognostic factor that can be considered as a criterion to consider patients in different prognostic groups. LDH is also a potential predictive marker to guide individual therapy decisions in solid tumors. Further, adequate, multi-center prospective studies are required to explore the clinical utility of LDH in solid tumors.
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###### Baseline Characteristics of Included Studies

  No       Fist Author       Year   Sample Size   LDH (High/Low)                         Site                         Stage   Cutoff (UI/L)   Outcome   Study type   Follow-up Time(mo)   Risk of Bias                                                                                                    Adjusted Variable
  ---- -------------------- ------ ------------- ---------------- -------------------------------------------------- ------- --------------- --------- ------------ -------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1        Laurie[@b41]      2007       210           109/47                             SCLC                           N          ULN          OS          P                NA                L                                                                                                    Gender, ECOG PS, Anemia grade
  2        Motzer[@b7]       2013      1059             NA                               RCC                            M        1.5ULN       PFS/OS        R                NA                L                                                              Ethnic origin, ECOG PS, Time from diagnosis to treatment, Bone metastases, Hb, Ca, Neutrophils, Cytokine
  3        Polee[@b32]       2003       350           296/54                      Esophageal cancer                   M + N        ULN          OS          R                NA                L                                                                                           WHO Performance, Extent of disease, Paclitaxel
  4         Han[@b31]        2003       383          232/151                     Many kinds of cancer                 M + N        ULN          OS          R                NA                H                                                                                    PS(WHO), White blood count, Hb, Number of sites of metastases
  5      Atzpodien[@b30]     2003       425           330/95                             RCC                            M          220          OS          R               20 +               L                                                      Neutrophil counts, CRP, Time from diagnosis of tumour to metastatic disease, Number of metastatic sites, Bone metastases
  6        Bidard[@b56]      2012       267           121/99                        Breast cancer                       M          ULN          PFS         P               14.9               L                                                                     Triple negative, PS, Number of metastatic sites, CTC, CA15-3, CYFRA 21-1, CEA,ALP, C-INDEX
  7         Culp[@b47]       2010       566          107/366                             RCC                            M          618          OS          P                20                L         Albumin, ALP, Hb, Metastasectomy at any time, Liver metastasis, Clinical tumor classification, Fuhrman nuclear grade, No. of metastatic sites at CN, Sarcomatoid dedifferentiation, Clear cell histology, treatment
  8        Pierga[@b28]      2001      1336          1039/297                        Breast cance                       M          ULN          OS          P                NA                L                                                              Karnofsky index, Disease free interval, No. of metastatic sites, Liver involvement, Adjuvant chemotherapy
  9         Cook[@b37]       2006       635           566/69                             HRPC                           M          454          OS          R                NA                L                                                                                          Age, PSA, Hb, Albumin, Analgesics, ECOG, NTx, BAP
  10         Wan[@b8]        2013       400           367/33                   Nasopharyngeal carcinoma                 N          245        DFS/OS        R                NA                L                                                                                                    Age, Tumor stage, Node stage
  11      Mekenkamp[@b9]     2012      1010          637/365                      Colorectal cancer                     M          ULN          OS          R                NA                L                                         Diameter, Invasion depth, Lymph node status, Number lymph nodes, Number positive lymph nodes, MMR status, KRAS mutation status,BRAF mutation status
  12    Sougioultzis[@b54]   2011       311          137/173                      Gastric carcinoma                     M          225          OS          R                NA                L                                        Palliative gastrectomy, Chemotherapy, Liver metastasis, Abdominal/Peritoneal metastasis, Histological grade, CA72−4, Weight loss, Blood transfusions
  13        Zhou[@b61]       2012       465           424/31                   Nasopharyngeal carcinoma               M + N        245        DFS/OS        R               44.7               L                                                                                                     N category, T category, Age
  14     Lagerwaard[@b23]    1999      1292          1081/211                    Many kinds of cancer                   M          ULN          OS          R                NA                L         PS, Number and distribution of brain metastases, Site of primary tumor, Histology, Interval between primary tumor and brain metastases, Systemic tumor activity, Response to steroid treatment, Treatment modality
  15        Aoe[@b35]        2005       309          448/157                         Lung cancer                      M + N        450          OS          R                NA                H                                                                                        Anemia, TNM stage ECOG PS, Sex, Histologic type, Age
  16       Bacci[@b38]       2007       742          464/278                       Ewing's sarcoma                    M + N        ULN          OS          R                NA                L                                                                                     Pelvis, Other sites, Interval symptoms to diagnosis, Fever
  17     Armstrong[@b55]     2012       404          264/140                             RCC                            M          ULN          OS          R                NA                H                                                                 Treatment, Interaction term, KPS, Prior nephrectomy, No. of metastatic sites, Corrected calcium, Hb
  18       Gripp[@b40]       2007       205           130/75                     Many kinds of cancer                 M + N        240          OS          P                NA                L                                                                                  WBC, Dyspnea,Morphine, KPS, Brain metastasis, Colorectal, Breast
  19      Giaccone[@b36]     2005       216             NA                               SCLC                           N          ULN          OS          P                NA                H                                                                                               Sex, Chest radiotherapy, PCI, Platelets
  20       Motzer[@b29]      2002       463             NA                               RCC                          M + N      1.5 ULN        OS          R                46                L                                                                   Karnofsky PS, Hb, Calcium, Time from initial RCC diagnosis to start of interferon-alpha therapy
  21       Bacci[@b26]       2000       357          238/121                       Ewing's sarcoma                      N          ULN          OS          R               126                L                                           Sex, Age, Fever, Anemia, Axial location, Radiation therapy only for local control, Type of chemotherapy regimen, Chemotherapy-induced necrosis
  22       Motzer[@b24]      1999       670             NA                               RCC                          M + N      1.5ULN         OS          R                33                L                                                                                                   KPS, Hb, Ca, Prior nephrectomy.
  23          Feliu          2011       406             NA                       Many kinds of cancer                 M + N        NA           OS          P                NA                H                                                                                                 ECOG PS, TTD, Albumin, Lymphocytes
  24       Scher[@b25]       1999       254           164/90                             CRPC                         M + N        230          OS          R                NA                H                                                                                                No 50% decline within 12 wk, Hb, Age
  25      Escudier[@b39]     2007       300           222/52                             RCC                            M        1.5ULN         OS          P                NA                L                                                                      ECOG PS, Number of metastatic sites, Time from nephrectomy to metastatic disease, ALP, Ca
  26      Kawahara[@b19]     1997       284          147/137                             SCLC                         M + N        ULN          OS          R                NA                H                                                                                                      PS, Stage, ALP, CEA, Sex
  27     Chibaudel[@b52]     2011       535          283/252                      Colorectal Cancer                     M          ULN          OS          R                NA                L                                                                Age, Sex, PS, No.sites, Liver involvement, Primitive tumor, Time to metastasis, Adjuvant CT, ALP, CEA
  28        Kim[@b48]        2010       257             NA                              NSCLC                         M + N        ULN          OS          R                NA                H                                                                                                         ECOG PS, Skin rash
  29     Hashimoto[@b46]     2009       326             NA                        Pancreatic cancer                   M + N        220          OS          R                NA                H                                                                          Recurrence vs. metastasis, KPS, Liver metastasis, Peritoneal metastasis, ALP, CRP
  30     Tanrikulu[@b50]     2010       363             NA                       Pleural mesothelioma                 M + N        500          OS          R                NA                H                                                               KPS, Pleural fluid glucose level, CRP, Pleural effusion, Pleural thickening on chest CT, Platelet count
  31        Aoe[@b33]        2004       611             NA                           Lung Cancer                      M + N        450          OS          R                NA                H                                                                                    Platelet count, TNM stage, ECOG PS, Sex, Histologic type, Age
  32       Giroux[@b10]      2012       245           177/45                            NSCLC                         M + N        500          OS          R                NA                H                                                                  Number of treatment lines, PS, Surgery, Maintenance therapy, Time to first progression of tumour
  33        Suh[@b49]        2010       209           94/115                     Many kinds of cancer                 M + N        502          OS          R                NA                H                                                                                Anorexia, Resting dyspnea, ECOG, Leukocytosis, Bilirubin, Creatinine
  34       Bacci[@b34]       2004      1421          1116/305                        Osteosarcoma                     M + N        240          OS          R                NA                L                                                                                       Other sites, Interval symptoms to diagnosis, Treatment
  35       Saito[@b42]       2007       241             NA                         Prostate Cancer                      M          400          OS          R                31                L                                                     Age, performance status, clinical presentation, disease localization, pathologic findings, PSA, PSA/PAP ratio, CEA, ALP,CRP
  36     Hannisdal[@b18]     1993       202             NA                          Bladder Cancer                    M + N        400          OS          R                NA                H                                                                                  Erythrocyte sedimentation rate, Hb, ALP, GGT, Creatinine, Albumin
  37       Tonini[@b20]      1997       246          162/106                        Neuroblastoma                     M + N       1000          OS          R                NA                L                                               MYCN oncogene amplification, Abdominal tumor, Stage, Vanillylmandelic (VMA) urinary excretion, Ferritin, Neuron-specific enolase (NSE)
  38         Li[@b58]        2012       533             NA                     Nasopharyngeal carcinoma               M + N        240          OS          R                NA                H                                                                                                AJCC T category, AJCC N category, Age
  39        Jin[@b65]        2013       689          379/310                   Nasopharyngeal carcinoma                 M          245          OS          R                NA                L                             Sex, Age, Metastasis at presentation, Lung metastasis, Post-treatment S-LDH level, Drug number of chemotherapy, Number of involved sites, Liver metastasis, Bone metastasis
  40        Wei[@b75]        2014       601             NA                     Nasopharyngeal carcinoma                 N          225        DFS/OS        R               51.5               L                                                                                               Age, T classification, N classification
  41        Sau[@b14]        2013       329          154/175                            NSCLC                         M + N        ULN          OS          R                NA                L                                                     Age, Sex, PS, Histopathology, smoking status, Response after 1-line CT, First-line CT, PFS after 1-line CT, Second-line CT
  42        Wang[@b74]       2014       499           75/39                              SCLC                         M + N        240          OS          R                NA                L                                                                                                   ECOG-PS, Extensive disease, NLR
  43     Yamaguchi[@b76]     2014       206             NA         Neuroendocrine carcinoma of the digestive system   M + N        ULN          OS          R                NA                H                                                                        Age, Sex, PS, Primary site, Liver metastasis, First-line chemotherapy, Prior surgery
  44       Halabi[@b70]      2014      1050          565/482                             CRPC                           M          ULN          OS          R                NA                L                                                                                  ECOG PS, Disease site, Opioid analgesic use, Albumin, Hb, PSA,ALP
  45     Templeton[@b73]     2014       357             NA                               CRPC                           M        1.2 ULN        OS          R                NA                H                     Age, ECOG PS, Number of comorbidities, Gleason sum score, Lymph node metastatic only, Bone metastasis, Visceral metastasis, Liver metastasis, Hb, Albumin, ALP, PSA, PSA-doubling time, NLR
  46         Du[@b62]        2013       286           197/89                             RCC                          M + N      1.5 ULN      DFS/OS        R                NA                L                                                                                       Fibrinogen, Hb, Ca, T stage, Fuhrman grade, Tumor size
  47     Shinohara[@b67]     2013       473           388/34                             RCC                            M        1.5 ULN        OS          R                NA                L                                                          Time from initial diagnosis to metastasis, Hb, Ca, CRP, Liver metastasis, Bone metastasis, Lymph node metastasis
  48      Poprach[@b72]      2014       319           285/34                             RCC                            M        1.5 ULN      PFS/OS        R                15                L                                                                                          Time from diagnosis to TKI, Neutrophils, ECOG PS
  49       Powles[@b66]      2013       204           52/55                            Seminoma                       M + N      1.5 ULN        PFS         R                NA                H                                                                                                          Age, IPFSG score
  50     van Kessel[@b68]    2013       290          152/138                      Colorectal Cancer                     M          ULN          OS          R                NA                L                                                             Gender, Age, Number of first line cycles, Metastases, Resection prim. Tumour, Study-arm, Response category
  51      Giessen[@b64]      2013       215          270/201                      Colorectal Cancer                     M          250          OS          R               55.4               L                                                                                         Liver-limited disease, N-stage of primary, KPS, ALP
  52       Weide[@b69]       2013       372          263/175                           Melanoma                         M          ULN          OS          R                27                L                                                                                         S100B, Cerebral metastases, First systemic therapy
  53      Meckbach[@b71]     2014       215           131/63                           Melanoma                         M          ULN          OS          R                46                L                                                                                                          Brain metastasis
  54      Durnali[@b63]      2013       240           101/81                         Osteosarcoma                     M + N        ULN        RFS/OS        R                51                L                      Gender, ALP, Histological subtype, Metastasis at diagnosis, Surgical margins, Tumor necrosis rate, Postoperative chemotherapy, Surgery after recurrence, Chemotherapy after recurrence,,
  55         He[@b13]        2013       239           154/82                      Colorectal Cancer                     M          ULN        PFS/OS        R                NA                H                                                                                       Age, Gender, Lines of chemotherapy,CEA,CA19-9, GGT,ALP
  56       Weide[@b60]       2012       855          502/228                           Melanoma                         M          ULN          OS          R                NA                L                                                 S100B, Time interval between initial diagnosis and stage IV diagnosis, Site of distant metastasis, Number of involved distant sites
  57     Shinohara[@b59]     2012       361           299/23                             RCC                            M        1.5ULN         OS          R               21.5               L                                                                              Time from initial diagnosis to treatment, Hb, Prognostic metastatic group
  58       Jakob[@b57]       2012       677           263/97                           Melanoma                         M          ULN          OS          R                12                L                                                                                                 Age, Gender, M1 Category, Mutation
  59      Bedikian[@b51]     2011       740          430/275                           Melanoma                         M          ULN          OS          R                NA                L                                                                                 Age, Chemoresponse, Albumin, M-stage, Location of primary melanoma
  60       Neuman[@b45]      2008       589          246/125                           Melanoma                         M          200          OS          P                NA                L                                                    Sex, Age at diagnosis of stage IV disease, Antecedent stage, DFI, Site of disease, No. of organs involved, No. of metastases
  61      Schmidt[@b43]      2007       363           317/46                           Melanoma                         M         2ULN        PFS/OS        R               50.4               L                                                                                             Sex, Site, ECOG PS, Leukocytes, Neutrophils
  62      Bedikian[@b44]     2008       616          358/258                           Melanoma                         M          618          OS          R                NA                L                                                                    ECOG PS, Disease stage, Metastatic sites, Visceral metastasis, Albumin, Response to treatment
  63       Viganó[@b27]      2000       227           142/85                     Many kinds of cancer                 M + N        618          OS          R                NA                L                                               Primary tumor, Liver metastasis, Comorbidity, Weight loss, ECOG PS, Nausea, Clinical estimation of survival, Albumin, Lymphocyte count
  64       Tamura[@b22]      1998       253             NA                               SCLC                         M + N        ULN          OS          R                NA                H                                                                                 Extent of disease, Number of metastatic sites, Albumin, Weight loss
  65       Eton O[@b21]      1998       318             NA                             Melanoma                         M          225          OS          R                NA                H                                                         Albumin, Soft tissue and/or single visceral organ metastases (especially lung), Sex, Enrollment late in the decade
  66      D'AMICO[@b77]      2005       494             NA                               HRPC                           M        74-2077        OS          R            15.6-16.8             L                                                                                    Hb, Age, ECOG PS, ALP, Treatment, PSA response duration, PSA
  67       Halabi[@b78]      2003       760             NA                               HRPC                           M        173-437        OS          R                NA                H                                                                                             PS, Gleason, ALP, PSA, Visceral disease, Hb
  68    Schellhammer[@b79]   2013       512             NA                               CRPC                           M        84-1662        OS          P                NA                L                                                                                                  PSA, Hb, ECOG, ALP, Gleason score

Abbreviations: SCLC: small-cell lung cancer; NSCLC: non-small-cell lung cancer; RCC: renal cell carcinoma; HRPC: hormone-refractory prostate cancer; CRPC: castration refractory prostate cancer; ULN: upper limit of normal; OS: overall survival; PFS: progression-free survival; DFS: disease-free survival; RFS: recurrence-free survival; M: metastatic; N: non-metastatic; M + N: mixed (non-metastatic and metastatic); R: retrospective; P: prospective; L : low risk; High: high risk; NA: not available; PS: performance score; KPS: Karnofsky performance score ; LDH : Lactic dehydrogenas; ALP: alkaline phosphatase; PSA: prostate specific antigen; Hb: hemoglobin; Ca: calcium; PS: Performance Status; ECOG PS: Eastern Cooperative Oncology Group Performance Status ; ALP: alkaline phosphatase; CTC: circulating tumor; NLR: neutrophils / lymphocytes; CRP: C-reaction protein; IPFSG: International Prognostic Factors Study Group; CA19-9: carbohydrate antigen 19-9; CEA: carcinoembryonic antigen; GGT: gamma-glutamyl transpeptidase; DFI: DFI: disease-free interval
